Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of April 2026. The filing details a share repurchase executed on April 22, 2026, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing focuses exclusively on share repurchase activity and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased (April 22, 2026): 965,671 ordinary shares.
- Price Range (GBp): Lowest 2,073.00p; Highest 2,093.00p.
- Volume-Weighted Average Price (GBp): 2,081.15p.
- Programme Progress: Since February 17, 2026, the Company has purchased 21,487,192 ordinary shares.
- Treasury Shares Held: 261,378,286 ordinary shares.
- Shares in Issue (excluding Treasury): 4,054,820,748 ordinary shares.
- Treasury Voting Rights: 6.45% of total voting rights.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares resulting from the April 22 repurchase. The filing confirms that the purchased shares are held as Treasury shares. No other material changes to the Company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025.
Important Facts for Investors
- Verify the total number of voting rights (4,054,820,748) to determine notification thresholds under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
- Note that treasury shares (6.45% of voting rights) do not carry voting rights.
- Confirm the remaining capacity of the buyback programme, as the filing only states the aggregate purchased since February 17, 2026, without specifying the total programme authorization limit.
- Review the referenced 2025 Form 20-F for a comprehensive list of risk factors affecting the Company.